Pablo Angeles Tacchino
@pabloange
Followers
727
Following
10K
Statuses
2K
Peruanos en el KidneyWk, un gusto verlos colegas que triunfan y dejan al Perú muy en alto @VelezNephHepato @lluncornefro @javo_neyra @RosaMar64577668 @GeorgeVasquezR2 @portorenal @roxnonna23 @HelbertRondon @lluncornefro @ZandybellNefro @LuisNgS #KidneyWk
1
4
16
RT @NephroSeeker: Hot Debate - "The KDIGO BP Targets in CKD Are (Un)Achievable and (Un)Realistic with @hswapnil pro unbiased take #ISNWCN…
0
11
0
RT @edgarvlermamd: Amlodipine vs Nifedipine #Nephpearls #HTNSecrets 📌 In HFrEF, nifedipine use has been associated with worse long-term o…
0
92
0
RT @NDTsocial: Antibody-mediated podocytopathies: a disease entity that implies immunotherapy 🆓 📸A proposed diagno…
0
83
0
RT @Meyaix: Results of REGENCY trial for #lupusnephritis presented at #WCN2025 & available at @NEJM Obinutuzumab, a potent anti-CD20 antib…
0
26
0
RT @brendonneuen: 🚨Combination therapy as a new standard of care in diabetic and non-diabetic CKD 🚨 Risk-based implementation, ongoing tri…
0
28
0
RT @AJKDonline: A Core Outcome Set for Trials in CKD: Report of the Standardized Outcomes in Nephrology–Chronic Kidney Disease (SONG-CKD) S…
0
8
0
Interesante estudio en ERPQ justo el grupo con data controversial . Estudios preclinicos con aparente aumento de los quistes con sglt2i. Estudio abierto beneficio con tolvapatan .KI reports 2025
Open-label, Randomized, Controlled, Crossover Trial on the Effect of #Dapagliflozin in Patients with Autosomal Dominant Polycystic Kidney Disease #ADPKD Receiving #Tolvaptan
#VisualAbstract by @md_abdulqader83
0
0
3
RT @DanielDiazNF: ELISA test value >20 RU/mL, combined with secondary screening, can confirm PLA2R-related MN without requiring a biopsy E…
0
16
0
RT @MHcsba: ICM 2024: 10 tips en relación a la trombocitopenia inducida por sepsis #MedEd #MedX #MedTwitter https:/…
0
37
0
RT @asnpublications: Classification of ANCA associated vasculitis (AAV) continues to be controversial. In this article, the authors discuss…
0
34
0
RT @edgarvlermamd: SGLT2 inhibitor (SGLT2i) Cold 🥶 Map: Indications for SGLT2i in CKD/ Albuminuria/ Type 2 Diabetes (T2D)/ Heart Failure (H…
0
104
0
Que revisión sistematica más interesante de la real aplicación de hierro ev en pacientes con ERC. Y desenlaces CV. Falta RCTs.. Kidney International 2025 #ckd
0
5
13
RT @hardik4u24: 🚨Game-changer in kidney transplants!🚨 💉Imlifidase clears DSAs fast, enabling HLA-incompatible transplants for highly sensi…
0
35
0
RT @JonathanNefro: En rabdomiolisis (mioglobina >4000 ug/L) y lesión renal aguda, el reemplazo renal continuo con hemofiltración, hemodiáli…
0
24
0
RT @brendonneuen: 📢 New Systematic Review & Meta-Analysis in @KIReports 📢 We evaluated the effects of iron therapy on clinical outcomes in…
0
16
0
RT @PRomagnani: Anti-slit diaphragm antibodies in autoimmune podocytopathy: •Anti-nephrin → frequent in kids •Anti-podocin → in kids & adul…
0
72
0
